- •Preface
- •Contents
- •1 Extracellular and Intracellular Signaling – a New Approach to Diseases and Treatments
- •1.1 Introduction
- •1.1.1 Linear Model of Drug Receptor Interactions
- •1.1.2 Matrix Model of Drug Receptor Interactions
- •1.2 Experimental Approaches to Disease Treatment
- •1.3 Adipokines and Disease Causation
- •1.4 Questions in Disease Treatment
- •1.5 Toxic Lifestyles and Disease Treatment
- •References
- •2.1 Introduction
- •2.2 Heterogeneity of Adipose Tissue Composition in Relation to Adipokine and Cytokine Secretion
- •2.3 Feedback between FA and the Adipocyte
- •2.6 Metabolic Programming of Autocrine Signaling in Adipose Tissue
- •2.8 Cell Heterogeneity in the Pancreatic Islet
- •2.16 Concluding Remarks
- •Acknowledgements
- •References
- •3 One Receptor for Multiple Pathways: Focus on Leptin Signaling
- •3.1 Leptin
- •3.2 Leptin Receptors
- •3.3 Leptin Receptor Signaling
- •3.3.4 AMPK
- •3.3.5 SOCS3
- •3.4 Leptin Receptor Interactions
- •3.4.1 Apolipoprotein D
- •3.4.2 Sorting Nexin Molecules
- •3.4.3 Diacylglycerol Kinase Zeta
- •3.4.4 Apolipoprotein J
- •References
- •4.1 Introduction
- •4.2 Leptin: A Brief Introduction
- •4.3 Expression of Leptin Receptors in Cardiovascular Tissues
- •4.6 Post Receptor Leptin Signaling
- •4.6.2 Mitogen Activated Protein Kinase Stimulation
- •4.7 Adiponectin
- •4.7.1 Adiponectin and Cardiovascular Disease
- •4.7.2 Adiponectin and Experimental Cardiac Hypertrophy
- •4.8 Resistin
- •4.8.1 Cardiac Actions of Resistin
- •4.8.1.1 Experimental Studies on the Cardiac Actions of Resistin
- •4.9 Apelin
- •4.9.1 Apelin and Heart Disease
- •4.10 Visfatin
- •4.11 Other Novel Adipokines
- •4.12 Summary, Conclusions and Future Directions
- •Acknowledgements
- •References
- •5 Regulation of Muscle Proteostasis via Extramuscular Signals
- •5.1 Basic Protein Synthesis
- •5.2.1 Hormones
- •5.2.1.1 Mechanisms of Action: Glucocorticoids
- •5.2.1.2 Mechanisms of Action: TH (T3)
- •5.2.1.3 Mechanisms of Action: Testosterone
- •5.2.1.4 Mechanisms of Action: Epinephrine
- •5.2.2 Local Factors (Autocrine/Paracrine)
- •5.2.2.1 Mechanisms of Action: Insulin/IGF Spliceoforms
- •5.2.2.2 Mechanisms of Action: Fibroblast Growth Factor (FGF)
- •5.2.2.3 Mechanisms of Action: Myostatin
- •5.2.2.4 Mechanisms of Action: Cytokines
- •5.2.2.5 Mechanisms of Action: Neurotrophins
- •5.2.2.7 Mechanisms of Action: Extracellular Matrix
- •5.2.2.8 Mechanisms of Action: Amino Acids (AA)
- •5.3 Regulation of Muscle Proteostasis in Humans
- •5.3.1 Nutrients as Regulators of Muscle Proteostasis in Man
- •5.3.2 Muscular Activity (i.e. Exercise) as a Regulator of Muscle Proteostasis
- •5.4 Conditions Associated with Alterations in Muscle Proteostasis in Humans
- •5.4.2 Disuse Atrophy
- •5.4.3 Sepsis
- •5.4.4 Burns
- •5.4.5 Cancer Cachexia
- •References
- •6 Contact Normalization: Mechanisms and Pathways to Biomarkers and Chemotherapeutic Targets
- •6.1 Introduction
- •6.2 Contact Normalization
- •6.3 Cadherins
- •6.4 Gap Junctions
- •6.5 Contact Normalization and Tumor Suppressors
- •6.6 Contact Normalization and Tumor Promoters
- •6.7 Conclusions
- •References
- •7.1 Introduction
- •7.2 Background on Migraine Headache
- •7.3 Migraine and Neuropathic Pain
- •7.4 Role of Astrocytes in Pain
- •7.5 Adipokines and Related Extracellular Signalling
- •7.6 The Future of Signaling Research to Migraine
- •Acknowledgements
- •References
- •8.1 Alzheimer’s Disease
- •8.1.2 Target for AD Therapy
- •8.2 AD and Metabolic Dysfunction
- •8.2.1 Impaired Glucose Metabolism
- •8.2.2 Lipid Disorders
- •8.2.3 Obesity
- •8.3 Adipokines
- •8.3.1 Leptin
- •8.3.2 Adiponectin
- •8.3.3 Resistin
- •8.3.4 Visfatin
- •8.3.5 Plasminogen Activator Inhibitor
- •8.3.6 Interleukin-6
- •8.4 Conclusions
- •References
- •9.1 Introduction
- •9.1.1 Structure and Function of Astrocytes
- •9.1.1.1 Morphology
- •9.1.1.2 Astrocyte Functions
- •9.1.2 Responses of Astrocytes to Injury
- •9.1.2.1 Reactive Astrocytosis
- •9.1.2.2 Cell Swelling
- •9.1.2.3 Alzheimer Type II Astrocytosis
- •9.2 Intracellular Signaling System in Reactive Astrocytes
- •9.2.1 Oxidative/Nitrosative Stress (ONS)
- •9.2.2 Protein Kinase C (PKC)
- •9.2.5 Signal Transducer and Activator of Transcription 3 (STAT3)
- •9.3 Signaling Systems in Astrocyte Swelling
- •9.3.1 Oxidative/Nitrosative Stress (ONS)
- •9.3.2 Cytokines
- •9.3.3 Protein Kinase C (PKC)
- •9.3.5 Protein Kinase G (PKG)
- •9.3.7 Signal Transducer and Activator of Transcription 3 (STAT3)
- •9.3.10 Ion Channels/Transporters/Exchangers
- •9.4 Conclusions and Perspectives
- •Acknowledgements
- •References
- •10.1 Adipokines, Toxic Lipids and the Aging Brain
- •10.1.1 Toxic Lifestyles, Adipokines and Toxic Lipids
- •10.1.2 Ceramide Toxicity in the Brain
- •10.3 Oxygen Radicals, Hydrogen Peroxide and Cell Death
- •10.4 Gene Transcription and DNA Damage
- •10.5 Conclusions
- •References
- •11.1 Introduction
- •11.2 Cellular Signaling
- •11.2.1 Types of Signaling
- •11.2.2 Membrane Proteins in Signaling
- •11.3 G Protein-Coupled Receptors
- •11.3.1 Structure of GPCRs
- •11.3.1.1 Structure Determination
- •11.3.1.2 Structural Diversity of Current GPCR Structures
- •11.3.1.3 Prediction of GPCR Structure and Ligand Binding
- •11.3.2 GPCR Activation: Conformation Driven Functional Selectivity
- •11.3.2.2 Ligand or Mutation Stabilized Ensemble of GPCR Conformations
- •11.3.2.4 GPCR Dimers and Interaction with Other Proteins
- •11.3.3 Functional Control of GPCRs by Ligands
- •11.3.3.1 Biased Agonism
- •11.3.3.2 Allosteric Ligands and Signal Modulation
- •11.3.4 Challenges in GPCR Targeted Drug Design
- •11.4 Summary and Looking Ahead
- •Acknowledgements
- •References
- •12.1 Introduction
- •12.5.1 Anthocyanins
- •12.5.2 Gallates
- •12.5.3 Quercetin
- •12.5.5 Piperine
- •12.5.6 Gingerol
- •12.5.7 Curcumin
- •12.5.8 Guggulsterone
- •12.6.1 Phytanic Acid
- •12.6.2 Dehydroabietic Acid
- •12.6.3 Geraniol
- •12.7 Agonists of LXR that Reciprocally Inhibit NF-jB
- •12.7.1 Stigmasterol
- •12.7.3 Ergosterol
- •12.8 Conclusion
- •References
- •13.1 Introduction
- •13.2 Selective Dopaminergic Neuronal Death
- •13.3 Signaling Pathways Involved in Selective Dopaminergic Neuronal Death
- •13.3.1 Initiators and Signaling Molecules
- •13.3.1.1 Response to Oxidative and Nitrosative Stress
- •13.3.1.2 Response to Altered Proteostasis
- •13.3.1.3 Response to Glutamate
- •13.3.1.4 Other Initiators
- •13.3.2 Signal Transducers, Intracellular Messengers and Upstream Elements
- •13.3.2.2 Small GTPases
- •13.3.3 Intracellular Signaling Cascades
- •13.3.3.1 Mitogen Activated Protein Kinases (MAPK) Pathway
- •13.3.3.2 PI3K/Akt Pathway
- •13.3.3.4 Unfolded Protein Response (UPR)
- •13.3.4 Potentially Involved Intracellular Signaling Components
- •13.3.4.3 PINK1
- •13.3.5.2 Dopamine Metabolism
- •13.3.5.3 Cell Cycle
- •13.3.5.4 Autophagy
- •13.3.5.5 Apoptosis
- •13.4 Conclusions
- •References
- •Subject Index
102 |
Chapter 5 |
directly in isolated murine myotubes. Moreover, urinary PIF excretion is related to weight loss in patients with prostatic and primary gastrointestinal tumors. Mechanistically, PIF expression leads to increased proteasome expression (20S proteasome subunits, MSS1 and p42, another ATPase subunit of the 19S regulator, as well as an increased chymotrypsin-like enzyme activity of the b5 subunits of the proteasome) and activity is likely via inducing NFkB in a ROS-dependent manner. Indeed, studies in animal models of cancer cachexia, as well as in cancer patients, suggest that the ubiquitin proteasome pathway plays the predominant role in the degradation of myofibrillar proteins, particularly in patients with a weight loss of 410%.
Depressed protein synthesis during cancer cachexia in skeletal muscle is related not only to anorexia, as protein synthesis is also depressed in other animal models of cachexia where anorexia is absent. This suggests an underlying defect in the protein synthetic machinery. For example, gastrocnemius muscles from mice bearing the cachexia-inducing tumor MAC16 show activation of protein kinase R (PKR) when the weight loss is 416% and a corresponding increase in phosphorylation of eIF2a (an inhibitor of eIF2Be), which would suppress mRNA translation. Weight loss in mice bearing the MAC16 tumor is also associated with an increased amount of eIF4E bound to 4E-BP1 in gastrocnemius muscle, due to hypophosphorylation of 4E-BP1, resulting in a progressive decrease in the concentration of the active eIF4GeIF4E complex. This would also contribute to a depression in protein synthesis, as would also a decrease in phosphorylation of mTOR and p70S6K1. There is also an increase in the phosphorylation of eEF2, which would also decrease protein synthesis through a decrease in translation elongation.
References
1.C. G. Proud, Biochem. Soc. Trans., 2009, 37, 227.
2.W. E. Mitch and A. L. Goldberg, N. Engl. J. Med., 1996, 335, 1897.
3.N. J. Szewczyk and L. A. Jacobson, Int. J. Biochem. Cell Biol., 2005, 37, 1997.
4.D. E. Goll, G. Neti, S. W. Mares and V. F. Thompson, J. Anim. Sci., 2008, 86, E19.
5.G. S. Lynch, J. D. Schertzer and J. G. Ryall, Pharmacol. Ther., 2007, 113, 461.
6.S. C. Kandarian and R. W. Jackman, Muscle Nerve, 2006, 33, 155.
7.D. H. van Raalte, D. M. Ouwens and M. Diamant, Eur. J. Clin. Invest., 2009, 39, 81.
8.A. G. Smith and G. E. Muscat, Int. J. Biochem. Cell Biol., 2005, 37, 2047.
¨
9. W. E. Visser, K. A. Heemstra, S. M. A. Swagemakers, Z. Ozgu¨r, E. P. Corssmit, J. Burggraaf, W. F. J. van Ijcken, P. J. van der Spek, J. W. A. Smit and T. J. Visser, J. Clin. Endocrinol. Metab., 2009, 94, 3487.
10. M. Montano, J. N. Flanagan, L. Jiang, P. Sebastiani, M. Rarick, N. K. LeBrasseur, C. A. Morris, R. Jasuja and S. Bhasin, J. Clin. Endocrinol. Metab., 2007, 92, 2793.
Regulation of Muscle Proteostasis via Extramuscular Signals |
103 |
11.M. Estrada, A. Espinosa, M. Muller and E. Jaimovich, Endocrinol., 2003, 144, 3586.
12.D. A. Fryburg, R. A. Gelfand, L. A. Jahn, D. Oliveras, R. S. Sherwin,
L.Sacca and E. J. Barrett, Am. J. Physiol. Endocrinol. Metab., 1995,
268, E55.
13.D. R. Clemmons, Trends Endocrinol. Metab., 2009, 20, 349.
14.D. J. Glass, Curr. Opin. Clin. Nutr. Metab. Care, 2010, 13, 225.
15.C. McFarlane, M. Sharma and R. Kambadur, Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11, 422.
16.B. Pajak, S. Orzechowska, B. Pijet, M. Pijet, A. Pogorzelska, B. Gajkowska and A. Orzechowski, J. Physiol Pharmacol., 2008, 59(9), 251.
17.A. Guma, V. Martinez-Redondo, I. Lopez-Soldado, C. Canto and
A.Zorzano, Am. J. Physiol Endocrinol. Metab., 2010, 298, E742.
18.B. K. Pedersen, M. Pedersen, K. S. Krabbe, H. Bruunsgaard, V. B. Matthews and M. A. Febbraio, Exp. Physiol., 2009, 94, 1153.
19.H. Wu, W. C. Xiong and L. Mei, Development, 2010, 137, 1017.
20.R. Bassel-Duby and E. N. Olson, Ann. Rev. Biochem., 2006, 75, 19.
21.E. R. Chin, E. N. Olson, J. A. Richardson, Q. Yang, C. Humphries,
J.M. Shelton, H. Wu, W. Zhu, R. Bassel-Duby and R. Sanders Williams, Genes Dev., 1998, 12, 2499.
22.A. C. Durieux, D. Desplanches, D. Freyssenet and M. Fluck, Biochem. Soc. Trans., 2007, 35, 1312.
23.R. Zaidel-Bar, S. Itzkovitz, A. Ma’ayan, R. Iyengar and B. Geiger, Nat. Cell Biol., 2007, 9, 858.
24.J. E. Tang, D. R. Moore, G. W. Kujbida, M. A. Tarnopolsky and
S.M. Phillips, J. Appl. Physiol., 2009, 107, 987.
25.M. J. Rennie, H. Wackerhage, E. E. Spangenburg and F. W. Booth, Ann. Rev. Physiol., 2004, 66, 799.
26.D. Cuthbertson, K. Smith, J. Babraj, G. Leese, T. Waddell, P. Atherton,
H.Wackerhage, P. M. Taylor and M. J. Rennie, FASEB J., 2005, 19, 422.
27.S. Fujita, H. C. Dreyer, M. J. Drummond, E. L. Glynn, J. G. Cadenas,
F.Yoshizawa, E. Volpi and B. B. Rasmussen, J. Physiol., 2007, 582, 813.
28.P. J. Atherton, K. Smith, T. Etheridge, D. Rankin and M. J. Rennie, Amino Acids, 2010, 38, 1533.
29.V. Kumar, P. Atherton, K. Smith and M. J. Rennie, J. Appl. Physiol., 2009, 106, 2026.
30.S. B. Wilkinson, S. M. Phillips, P. J. Atherton, R. Patel, K. E. Yarasheski,
M.A. Tarnopolsky and M. J. Rennie, J. Physiol., 2008, 586, 3701.
31.V. Kumar, A. Selby, D. Rankin, R. Patel, P. Atherton, W. Hildebrandt,
J.Williams, K. Smith, O. Seynnes, N. Hiscock and M. J. Rennie, J. Physiol., 2009, 587, 211.
32.M. J. Rennie, Appl. Physiol Nutr. Metab., 2009, 34, 377.
33.S. M. Phillips, E. I. Glover and M. J. Rennie, J. Appl. Physiol., 2009, 107, 645.
34.E. I. Glover, S. M. Phillips, B. R. Oates, J. E. Tang, M. A. Tarnopolsky,
A.Selby, K. Smith and M. J. Rennie, J. Physiol., 2008, 586, 6049.
104 |
Chapter 5 |
35.S. H. Lecker, R. T. Jagoe, A. Gilbert, M. Gomes, V. Baracos, J. Bailey, S. R. Price, W. E. Mitch and A. L. Goldberg, FASEB J., 2004, 18, 39.
36.L. A. Callahan and G. S. Supinski, Crit. Care Med., 2009, 37, S354.
37.C. H. Lang, R. A. Frost and T. C. Vary, Am. J. Physiol. Endocrinol. Metab., 2007, 293, E453.
38.C. Pereira, K. Murphy, M. Jeschke and D. N. Herndon, Int. J. Biochem. Cell Biol., 2005, 37, 1948.
39.M. J. Tisdale, Curr. Opin. Gastroenterol., 2010, 26, 146.
40.J. M. Argiles, S. Busquets and F. J. Lopez-Soriano, Curr. Opin. Clin. Nutr. Metab. Care, 2003, 6, 401.